Abstract
Although various first- to third-line HER2-targeted therapies have been established, the optimal sequence after third-line therapy has not been determined yet. Here, we describe seven patients with HER2-positive metastatic breast cancer who underwent bevacizumab (BV) and paclitaxel (PTX) combination therapy after several HER2-targeted therapies. Re-biopsy of metastatic sites was performed on four patients during the treatment prior to BV + PTX; three patients presented the same HER2-positive status as that of the primary tumor and two of whom achieved partial response. Four of seven patients achieved partial response and a 10-month median progression-free survival. Therefore, bevacizumab combined with paclitaxel is potentially effective in the treatment of HER2-positive metastatic breast cancer, if standard HER2-targeted therapy fails.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus Bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676
NCCN clinical Practice Guidelines in Oncology (NCCN Guideline) Breast Cancer version3. 2021-Mar 29, 2021, https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
Gianni L, Romieu GH, Lichinitser M et al (2013) AVEREL: a randomized Phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 31(14):1719–1725
Lin NU, Seah DS, Gelman R et al (2013) A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res Treat 139(2):403–410
Martin M, Makhson A, Gligorov J et al (2012) Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer. Oncologist 17(4):469–475
Leone JP, Emblem KE, Weitz M et al (2020) Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases. Breast Cancer Res 22(1):131. https://doi.org/10.1186/s13058-020-01372-w
Sengupta S, Rojas R, Mahadevan A et al (2015) CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2-neu-positive breast cancer. Oxf Med Case Rep 4:254–257
Terada M, Sugiura H, Yoshimoto N et al (2017) Three poor performance status (PS) cases of metastatic breast cancer controlled with adjustment of dosing interval and dosage of bevacizumab and paclitaxel. Jpn J Cancer Chemothr 44(7):591–593
Hayama S, Nakamura R, Yamamoto N et al (2013) The successful treatment of brain metastasis from HER2 positive breast cancer with bevacizumab + paclitaxel. Jpn J Cancer Chemother 28(2):213–218
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This report is based on the poster presented at the 55th Annual Meeting of Japan Society of Clinical Oncology: P64-7.
About this article
Cite this article
Hamada-Nishimoto, M., Kang, Y., Shiraki, E. et al. Potential effectiveness of combining bevacizumab with paclitaxel for treating HER2-positive metastatic breast cancer. Int Canc Conf J 10, 329–333 (2021). https://doi.org/10.1007/s13691-021-00504-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13691-021-00504-z